Live tape
Top 8, mentions 7d10,925TSLA2,290 mentions▲ +0.05GOOGL1,545 mentions▲ +0.04SPCX1,507 mentions▲ +0.07CRWV1,430 mentions▲ +0.03NVDA1,192 mentions▲ +0.07QQQ1,170 mentions▲ +0.05NBIS924 mentions▲ +0.06META867 mentions▲ +0.05

Equity · Healthcare

EDIT

NASDAQ

Editas Medicine (EDIT)

$2.74 +0.74% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 7, 2026
Price · Chart
27 sessions
$3.25 $2.50 31 Aug 7 Oct

The line runs $3.06 on 31 August through $2.74 on 7 October, on a scale from $2.50 to $3.25. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 27 sessions, 31 Aug – 7 Oct 2026
Market cap $420.8M
52-week range $1.66 – $4.09
Avg volume 166.6K

as of Oct 7, 2026

Editas Medicine (EDIT) insider trades

SEC Form 4 · last 90 days · newest reported trade 3 Sep 2026

In the 90 days to 21 Oct 2026, Editas Medicine insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Dec 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 5
Net sold $34K
Non-trade filings 0
Date Insider Type Shares Value
03 Sep 2026 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Sell 709 $2K
03 Sep 2026 O'Neill Gilmore Neil CEO Sell 5,124 $16K
03 Sep 2026 Parison Amy SVP, Chief Financial Officer Sell 453 $1K
03 Aug 2026 Parison Amy SVP, Chief Financial Officer Sell 678 $2K
28 Jul 2026 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Sell 4,928 $13K

Editas Medicine (EDIT) reported financials

SEC EDGAR XBRL SEC EDGAR

Editas Medicine reported revenue of $40.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$160.1M.

Figure Reported Period
Revenue $40.5M 31 Dec 2025 fiscal year
Net income −$160.1M 31 Dec 2025 fiscal year
Diluted EPS −$1.80 31 Dec 2025 fiscal year
Total assets $237.4M 30 Jun 2026 at period end
Total equity $105.3M 30 Jun 2026 at period end

Editas Medicine (EDIT) earnings

SEC EDGAR

Editas Medicine last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.15; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.15 —
31 Mar 2026 Q1 2026 −$0.26 —
31 Dec 2025 FY 2025 −$1.80 —
30 Sep 2025 Q3 2025 −$0.28 —
30 Jun 2025 Q2 2025 −$0.63 —
31 Mar 2025 Q1 2025 −$0.92 —
31 Dec 2024 FY 2024 −$2.88 —
30 Sep 2024 Q3 2024 −$0.75 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Editas Medicine (EDIT) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Editas Medicine position for the quarter ended 30 Jun 2026 — a combined $33.0M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Renaissance Technologies Trimmed −37.8% shares 2,468,919 $8.0M
Marshall Wace Added +868.7% shares 2,037,287 $6.6M
D. E. Shaw & Co. Held (±25%) −2.2% shares 1,901,002 $6.2M
AQR Capital Management Held (±25%) +14.7% shares 1,572,242 $5.1M
Two Sigma Investments Held (±25%) −13.9% shares 1,332,976 $4.3M
Millennium Management New position 498,997 $1.6M
Citadel Advisors Trimmed −67.9% shares 212,761 $689K
Point72 Asset Management Held (±25%) +7.0% shares 125,234 $406K
Balyasny Asset Management New position 37,638 $122K
Man Group Exited

Editas Medicine (EDIT) fails-to-deliver

SEC CNS data SEC

On 24 Sep 2026, 301 shares of Editas Medicine failed to deliver (about $810).

Settlement date Shares failed Notional % of shares out
24 Sep 2026 301 $810 <0.001%
22 Sep 2026 180 $509 <0.001%
18 Sep 2026 684 $2K <0.001%
16 Sep 2026 2,048 $5K 0.001%
10 Sep 2026 57,754 $160K 0.038%
09 Sep 2026 2,387 $7K 0.002%

Congressional trades in Editas Medicine (EDIT)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Editas Medicine is a sale by Daniel S. Goldman (house, NY), dated 10 Apr 2023.

Date Member Type Amount
10 Apr 2023 filed 19 May 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K
17 Nov 2020 filed 01 Dec 2020 Donald S. Beyer, Jr. house · Democrat–VA Purchase $1K–$15K
27 Apr 2020 filed 09 May 2020 Donald S. Beyer, Jr. house · Democrat–VA Sale $1K–$15K
09 Jan 2020 filed 22 Feb 2020 Donald S. Beyer, Jr. house · Democrat–VA Purchase $1K–$15K
23 Dec 2019 filed 02 Jan 2020 Donald S. Beyer, Jr. house · Democrat–VA Purchase $1K–$15K
22 Nov 2019 filed 14 Dec 2019 Donald S. Beyer, Jr. house · Democrat–VA Purchase $1K–$15K

Editas Medicine (EDIT): frequently asked questions

From live data

Have Editas Medicine insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Editas Medicine insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Dec 2025, show no open-market purchase.

How many institutions hold Editas Medicine?

9 of the 45 institutional funds we track reported a Editas Medicine position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Editas Medicine had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Editas Medicine is dated 24 Sep 2026, when 301 shares failed to deliver.

When did Editas Medicine last report earnings?

Editas Medicine last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.15; no next date is announced in SEC filings yet.

What exchange is Editas Medicine listed on?

Editas Medicine trades on NASDAQ under the ticker EDIT.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings